ClinicalTrials.gg
CompletedNCT03005782Updated May 1, 2024

Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

A Phase 1 interventional study of REGN3767 and cemiplimab in Malignancies, sponsored by Regeneron Pharmaceuticals. Completed at 43 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-01.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
333
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objectives in the dose escalation phase are to evaluate safety and pharmacokinetics (PK) in order to determine the selected dose level(s) for expansion of REGN3767 as monotherapy and in combination with cemiplimab in patients with advanced malignancies, including lymphoma.

The primary objectives in the dose expansion phase are to assess preliminary anti-tumor activity of REGN3767 alone and in combination with cemiplimab (separately by cohort) as measured by objective response rate (ORR).

02

Conditions studied

  • Malignancies

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 333 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Dose escalation cohorts: Patients with or cytologically confirmed diagnosis of (including lymphoma) with demonstrated progression of a tumor for whom there is no available therapy likely to convey clinical benefit AND who have not been previously treated with a /PD-L1 inhibitor. These patients do not require
  • Dose expansion cohorts: Patients with histologically or cytologically confirmed diagnosis of 1 of specified tumors with measurable disease per 1.1 or Lugano criteria. Some patients may have been previously treated with a PD-1 or PD-L1 inhibitor
  • performance status of 0 or 1
  • Adequate organ and bone marrow function

Key Exclusion Criteria:

  • Prior treatment with any LAG-3 targeting biologic or small molecule
  • Radiation therapy within 2 weeks prior to randomization and not recovered to baseline from any AE due to radiation
  • Untreated or active central nervous system - Ongoing or recent (within 5 years) evidence of significant disease
  • therapy (>10 mg prednisone/day or equivalent) within 1 week prior to the first dose of study drug
  • Myocardial infarction within 6 months

Note: Other protocol defined Inclusion / Exclusion criteria apply

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
333 participants (actual)

Study arms

  • Experimental
    Monotherapy (REGN3767)

    Group A will consist of up to 4 sequential dose cohorts. Each cohort will receive 1 of 3 ascending dose levels of study drug during dose escalation. In addition 1 tumor-specific cohort will be treated at the recommended phase 2 dose (RP2D) during dose expansion.

    Drug: REGN3767

  • Experimental
    Combination Therapy (REGN3767+cemiplimab)

    Group B will consist of up to 4 sequential dose cohorts. Each cohort will receive 1 of 3 ascending dose levels of study drug during dose escalation. In addition, 9 tumor-specific cohorts will be treated at the RP2D during dose expansion

    Drug: REGN3767 · Drug: cemiplimab

Interventions

06

What researchers measure

Primary outcomes

  1. Rate of dose limiting toxicities (Dose Escalation Phase)

    Time frame: Baseline to 28 days

  2. Rate of adverse events (Dose Escalation Phase)

    Time frame: Baseline to 51 weeks

  3. Rate of serious adverse events (Dose Escalation Phase)

    Time frame: Baseline to 51 weeks

  4. Occurrence of death (Dose Escalation Phase)

    Time frame: Baseline to 51 weeks

  5. Number of patients with laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE]) (Dose Escalation Phase)

    Time frame: Baseline to 51 weeks

  6. Area under the curve (AUC) computed from time zero to the time of the last concentration [AUCall] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)

    Time frame: Baseline to 51 weeks

  7. AUCall-to-dose ratio [AUCall/Dose] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)

    Time frame: Baseline to 51 weeks

  8. AUC from time zero extrapolated to infinity [AUCinf] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)

    Time frame: Baseline to 51 weeks

  9. AUCinf-to-dose ratio [AUCinf/dose] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)

    Time frame: Baseline to 51 weeks

  10. AUC computed from time zero to the time of the last positive concentration [AUClast] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)

    Time frame: Baseline to 51 weeks

  11. AUClast-to-dose ratio [AUClast/dose] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)

    Time frame: Baseline to 51 weeks

  12. Clearance [CL] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)

    Time frame: Baseline to 51 weeks

  13. Maximum Plasma Concentration [Cmax] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)

    Time frame: Baseline to week 51

  14. Cmax-to-dose ratio [Cmax/dose] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)

    Time frame: Baseline to 51 weeks

  15. Last positive (quantifiable) concentration [Clast] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)

    Time frame: Baseline to 51 weeks

  16. Mean residence time extrapolated to infinity [MRTinf] (Dose Escalation Phase)

    Time frame: Baseline to 51 weeks

  17. Mean residence time when the drug concentration profile is based on values up to and including the last positive concentration [MRTlast] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)

    Time frame: Baseline to 51 weeks

  18. Observed terminal half-life [t1/2] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)

    Time frame: Baseline to 51 weeks

  19. t1/2 beta (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)

    Time frame: Baseline to 51 weeks

  20. Time of the last positive (quantifiable) concentration [tlast] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)

    Time frame: Baseline to 51 weeks

  21. Time to Cmax [tmax] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)

    Time frame: Baseline to 51 weeks

  22. Volume of distribution at steady state [Vss] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)

    Time frame: Baseline to 51 weeks

  23. Volume of distribution of the terminal phase [Vz] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)

    Time frame: Baseline to 51 weeks

  24. Objective response rate based on RECIST 1.1 for Solid Tumors (Dose Expansion phase)

    Time frame: Baseline to 51 weeks

  25. Objective response rate by Lugano criteria for Lymphoma (Dose Expansion Phase)

    Time frame: Baseline to 51 weeks

Secondary outcomes

  1. Objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (solid tumors) (Dose Escalation Phase)

    Time frame: Baseline to week 51

  2. Objective response rate per Lugano criteria (lymphomas) (Dose Escalation Phase)

    Time frame: Baseline to week 51

  3. Best overall response based on RECIST 1.1 criteria (Dose Escalation Phase)

    Time frame: Baseline to 51 weeks

  4. Best overall response based on irRECIST criteria (Dose Escalation Phase)

    Time frame: Baseline to 51 weeks

  5. Best overall response based on Lugano criteria (Dose Escalation Phase)

    Time frame: Baseline to 51 weeks

  6. Duration of response based on RECIST criteria (Dose Escalation Phase)

    Time frame: Baseline to week 51

  7. Duration of response based on irRECIST criteria (Dose Escalation Phase)

    Time frame: Baseline to week 51

  8. Duration of response based on Lugano criteria (Dose Escalation Phase)

    Time frame: Baseline to week 51

  9. Disease control rate based on RECIST criteria (Dose Escalation Phase)

    Time frame: Baseline to 51 weeks

  10. Disease control rate based on irRECIST criteria (Dose Escalation Phase)

    Time frame: Baseline to 51 weeks

  11. Disease control rate based on Lugano criteria (Dose Escalation Phase)

    Time frame: Baseline to 51 weeks

  12. Progression free survival based on RECIST (Dose Escalation Phase)

    Time frame: Baseline to 51 weeks

  13. Progression free survival based on irRECIST (Dose Escalation Phase)

    Time frame: Baseline to 51 weeks

  14. Progression free survival based on Lugano criteria (Dose Escalation Phase)

    Time frame: Baseline to 51 weeks

  15. Incidence of adverse events (Dose Expansion Phase)

    Time frame: Baseline to 51 weeks

  16. Incidence of serious adverse events (Dose Expansion Phase)

    Time frame: Baseline to 51 weeks

  17. Incidence of death (Dose Expansion Phase)

    Time frame: From Baseline to the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 42 months

  18. Number of patients with laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE]) (Dose Expansion Phase)

    Time frame: Baseline to 51 weeks

  19. Incidence of anti-drug antibodies (Dose Escalation Phase and Dose Expansion Phase)

    Time frame: Baseline to 51 weeks

07

Study locations

43 sites
  • California Cancer Associates for Research and Excellence
    Encinitas, California 92024, United States
  • California Cancer Associates For Research And Excellence
    Fresno, California 93720, United States
  • University of California San Diego (UCSD)
    La Jolla, California 92093-0698, United States
  • The Angeles Clinic
    Los Angeles, California 90025, United States
  • University of California Davis Health Systems
    Sacramento, California 95817, United States
  • California Pacific Medical Center (CPMC)
    San Francisco, California 94115, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • Lombardi Comprehensive Cancer Center - MedStar Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • Miami Cancer Institute
    Miami, Florida 33176, United States
  • Orlando Health, Inc
    Orlando, Florida 32806, United States
  • Winship Cancer Institute at Emory University
    Atlanta, Georgia 30322, United States
  • University of Kansas Clinical Research Center
    Fairway, Kansas 66205, United States
  • Dana Farber Cancer Institute
    Jamaica Plain, Massachusetts 02130, United States
  • Henry Ford Health Hospital
    Detroit, Michigan 48202, United States
  • Cancer and Hematology Centers of Western Michigan
    Grand Rapids, Michigan 49503, United States
  • Washington University in Saint Louis
    Saint Louis, Missouri 63110, United States
  • John Theurer Cancer Center, Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08903, United States
  • New Mexico Cancer Care Alliance-UNM Cancer Center
    Albuquerque, New Mexico 87131, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Northwell Health-Monter Cancer Center
    Lake Success, New York 11042, United States
  • Laura & Isaac Perlmutter Cancer Center
    New York, New York 10016, United States
  • Columbia University
    New York, New York 10032, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • University Hospitals Seidman Cancer Center and Case Western Reserve University
    Cleveland, Ohio 44087, United States
  • Stephenson Cancer Center
    Oklahoma City, Oklahoma 73104, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Hollings Cancer Center - Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • South Texas Oncology and Hematology
    San Antonio, Texas 78229, United States
  • Virginia Cancer Care Specialist, PC
    Fairfax, Virginia 22031, United States
  • The University of Western Australia - The Queen Elizabeth II Medical Centre (QEIIMC) - Sir Charles Gairdner Hospital (SCGH)
    Perth, Western Australia 06009, Australia
  • Royal Brisbane and Women's Hospital
    Brisbane, 4029, Australia
  • Peter Maccallum Cancer Centre (PMCC)
    Melbourne, 3000, Australia
  • St. Vincents University Hospital
    Dublin, D04 T6F4, Ireland
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Guy's Hospital
    London, Europe SE19RT, United Kingdom
  • University Of Oxford - Churchill Hospital
    Headington, Oxford OX37LJ, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Apr 2024, 88 months.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's 88 months is above that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2016
First posted
Dec 29, 2016
StartActual
Nov 7, 2016
Primary completionActual
Apr 2, 2024
CompletionActual
Apr 2, 2024
Last update
May 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03005782
Responsible party
Sponsor
First posted
Dec 29, 2016
Start date
Nov 7, 2016
Primary completion
Apr 2, 2024
Completion
Apr 2, 2024
Last update
May 1, 2024

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fianlimab · Cemiplimab

Start the discussion